bit.bio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 116

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $25M

  • Investors
  • 30

bit.bio General Information

Description

Developer of a synthetic biology platform designed to accelerate research, drug discovery, and cell therapy development through engineered human cell production. The company offers induced pluripotent stem cell-derived cells, proprietary gene-targeting technology, datasets, and research services, enabling biotechnology companies, pharmaceutical companies, and research institutions to improve disease modeling, train AI models, reduce development costs, and expand cell therapy applications.

Contact Information

Website
www.bit.bio
Formerly Known As
Elpis BioMed
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Dorothy Hodgkin Building
  • Babraham Research Campus
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • The Dorothy Hodgkin Building
  • Babraham Research Campus
  • Cambridge CB22 3FH
  • England, United Kingdom
+44 01223

bit.bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

bit.bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series D) 04-Nov-2026 $25M Completed Generating Revenue
11. Secondary Transaction - Private 01-Apr-2026 Completed Generating Revenue
10. Later Stage VC (Series C) 09-Jan-2026 Completed Generating Revenue
9. Accelerator/Incubator 19-Mar-2024 Completed Generating Revenue
8. Later Stage VC 01-Nov-2023 Completed Generating Revenue
7. Later Stage VC 31-Dec-2021 Completed Generating Revenue
6. Early Stage VC (Series A) 28-Feb-2020 Completed Generating Revenue
5. Grant 01-Dec-2019 Completed Generating Revenue
4. Seed Round 27-Mar-2019 $4.28M $4.68M Completed Generating Revenue
3. Seed Round 16-Nov-2017 $395K $395K Completed Generating Revenue
To view bit.bio’s complete valuation and funding history, request access »

bit.bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A
Series A
Seed 496,991 $0.000001 $8.03 $8.03 1x $8.03 10.88%
Ordinary 280,010 $0.000001 $1.42 $1.42 1x $1.42 6.13%
To view bit.bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

bit.bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a synthetic biology platform designed to accelerate research, drug discovery, and cell therapy development
Biotechnology
Cambridge, United Kingdom
116 As of 2026

Cambridge, MA
 

Yokohama, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

bit.bio Competitors (56)

One of bit.bio’s 56 competitors is GC Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GC Therapeutics Venture Capital-Backed Cambridge, MA
ReproCELL Formerly VC-backed Yokohama, Japan
AllCells Private Equity-Backed Alameda, CA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
ArsenalBio Venture Capital-Backed South San Francisco, CA
You’re viewing 5 of 56 competitors. Get the full list »

bit.bio Patents

bit.bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026202524-A1 Controllable transcription Pending 27-Mar-2025
WO-2026167379-A1 Method of generating glutamatergic neurons Pending 10-Feb-2025
WO-2026132788-A2 Method of generating lineage-restricted cells Pending 20-Dec-2024
WO-2026132788-A3 Method of generating lineage-restricted cells Pending 20-Dec-2024
WO-2026132775-A1 Controllable transcription Pending 17-Dec-2024 C07K14/4702
To view bit.bio’s complete patent history, request access »

bit.bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

bit.bio Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
M&G Asset Manager Minority
Tech Nation Group Accelerator/Incubator
Cambridge Enterprise Ventures Venture Capital Minority
Charles River Laboratories International Corporation Minority
Dynamk Capital Venture Capital Minority
You’re viewing 5 of 30 investors. Get the full list »

bit.bio Investments (1)

bit.bio’s most recent deal was a Joint Venture with Bit Bio Discovery. The deal was made on 09-Sep-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bit Bio Discovery 09-Sep-2020 Joint Venture Biotechnology
To view bit.bio’s complete investments history, request access »

bit.bio FAQs

  • When was bit.bio founded?

    bit.bio was founded in 2016.

  • Where is bit.bio headquartered?

    bit.bio is headquartered in Cambridge, United Kingdom.

  • What is the size of bit.bio?

    bit.bio has 116 total employees.

  • What industry is bit.bio in?

    bit.bio’s primary industry is Biotechnology.

  • Is bit.bio a private or public company?

    bit.bio is a Private company.

  • What is bit.bio’s current revenue?

    The current revenue for bit.bio is .

  • How much funding has bit.bio raised over time?

    bit.bio has raised $259M.

  • Who are bit.bio’s investors?

    M&G, Tech Nation Group, Cambridge Enterprise Ventures, Charles River Laboratories International, and Dynamk Capital are 5 of 30 investors who have invested in bit.bio.

  • Who are bit.bio’s competitors?

    GC Therapeutics, ReproCELL, AllCells, Genetix Biotherapeutics, and ArsenalBio are some of the 56 competitors of bit.bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process